RxDoctor Payments Data

John Gollier, MD

Family Medicine · Ottawa, KSNPI 1104857911

Payments from drug & device makers

$10,515in general payments, 2019–2025

Across 649 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$951
  • Amgen$805
  • Pfizer$393
  • plus $5K from 52 others

What the payments were for

  • Food & beverage$10,44999%
  • Education$661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,515 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$91,754
Medicare patients
494
Services billed
6,406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin107$95,840
EliquisApixaban130$79,574
XareltoRivaroxaban77$49,995
MounjaroTirzepatide32$33,794
OzempicSemaglutide27$31,216
TradjentaLinagliptin43$29,800
Tresiba Flextouch U-200Insulin Degludec22$27,423
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$22,587
FarxigaDapagliflozin Propanediol17$17,720
Repatha SureclickEvolocumab30$15,929
Breo ElliptaFluticasone/Vilanterol31$12,454
GlyxambiEmpagliflozin/Linagliptin14$12,199
MyrbetriqMirabegron26$11,368
Tresiba Flextouch U-100Insulin Degludec20$11,033
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$9,949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$388$137,839164 claims
PfizerEliquis, Premarin$393$82,073143 claims
Johnson & JohnsonXarelto$247$49,99577 claims
GSKTrelegy Ellipta, Breo Ellipta$131$35,04166 claims
Lilly USA, LLCMounjaro$951$33,79432 claims
Novo NordiskOzempic$1,318$31,21627 claims
AstraZenecaFarxiga$1,175$17,72017 claims
Astellas Pharma US IncMyrbetriq$165$11,36826 claims
Sumitomo Pharma America, Inc.Gemtesa$80$7,15716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Ottawa

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →